GV1001
Human telomerase reverse transcriptase (hTERT) 611-626 peptide GV1001
16 Amino Acids · MW: 1758.0 Da
Amino Acids
16
Molecular Weight
1758.0 Da
Half-life
minutes to hours
Research Score
4.1
Studies
40
Storage
Store lyophilized at -20°C, reconstituted at 2-8°C
What is GV1001?
A telomerase-derived 16-mer peptide developed as a cancer vaccine antigen. It is designed to trigger T-cell responses against hTERT-expressing tumors.
Key Benefits & Mechanisms
induces tumor-specific T cells
broad HLA coverage
vaccine-platform compatible
generally well tolerated
Research Summary
GV1001 has been tested in melanoma, pancreatic cancer, non-small-cell lung cancer, and other malignancies. Immunogenicity has been demonstrated, while clinical benefit has been mixed and appears regimen-dependent.
Related Peptides
Nelipepimut-S
HER2/neu-derived peptide vaccine Nelipepimut-S (E75; KIFGSLAFL)
A 9-mer HLA-A2/A3-restricted peptide from HER2/neu used as a vaccine antigen. It aims to expand cytotoxic T-cell responses against HER2-positive tumors.
Cancer ResearchWT1 peptide
Wilms tumor 1 (WT1) antigen-derived peptide RMFPNAPYL
A WT1-derived 9-mer peptide used in peptide-vaccine strategies for leukemias and solid tumors. It is intended to generate HLA-restricted cytotoxic T-cell responses against WT1-positive cancer cells.
Cancer ResearchSurvivin 2B peptide
Survivin 2B peptide (LMLGEFLKL)
A survivin-derived HLA-A24-restricted epitope investigated as a peptide vaccine antigen. It targets survivin, a frequently overexpressed inhibitor of apoptosis in tumors.
Cancer ResearchTumstatin
Collagen IV Alpha-3 NC1 Domain (Tumstatin)
Tumstatin is a collagen IV-derived fragment that inhibits angiogenesis and can induce apoptosis in endothelial cells. It is studied as a selective suppressor of pathologic vessel growth in tumor biology.
Cancer Research